1. Intranasal pharmaceutical dosage form comprising a dosage unit containing naloxone or a pharmaceutically acceptable salt thereof in an amount corresponding to from about 0.65 mg of naloxone HCl to 0.8 mg of naloxone HCl or from about 1.3 mg naloxone HCl to 1.6 mg naloxone HCl dissolved in an application liquid with a volume of approximately ≤250 μl, preferably approximately ≤200 μl. 2. The dosage form according to claim 1, wherein said dosage unit contains naloxone or a pharmaceutically acceptable salt thereof in an amount corresponding to from about 0.65 mg of naloxone HCl to 0.8 mg of naloxone HCl, if one stage of administration involves the introduction into two nasal openings. . The dosage form according to claim 1, wherein said dosage unit contains naloxone or a pharmaceutically acceptable salt thereof in an amount corresponding to from about 1.3 mg of naloxone HCl to 1.6 mg of naloxone HCl, if one stage of administration involves administration into one nasal opening. . Dosage form according to any one of claims 1 to 3, where the volume of liquid for application corresponds to a range of from about 200 μl to 35 μl, preferably from 200 μl to 50 μl, more preferably from 200 μl to 100 μl. Dosage form according to any one of claims 1 to 3, wherein the application liquid is selected from the group consisting of water and an aqueous saline solution, preferably an aqueous NaCl solution, more preferably an aqueous NaCl solution of 0.9% (w / v). A dosage form according to any one of claims 1 to 3, wherein the dosage form is selected from the group of dosage forms including a nasal spray, a nasal mucoadhesive dosage form and a mucosal irrigation device. Intranasal Pharmaceutical1. Интраназальная фармацевтическая дозированная форма, включающая единицу дозирования, содержащую налоксон или его фармацевтически приемлемую соль в количестве, соответствующем приблизительно от 0,65 мг налоксона HCl до 0,8 мг налоксона HCl или приблизительно от 1,3 мг налоксона HCl до 1,6 мг
